National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings, 44688 [2024-11067]
Download as PDF
<![CDATA[
44688
Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Notices
The Office of the Assistant
Secretary for Health, Office of
Population Affairs (OPA) has modified
its organizational structure.
DATES: This new organizational
structure was approved by the Secretary
of Health and Human Services and takes
effect on May 14, 2024.
FOR FURTHER INFORMATION CONTACT:
Jessica Swafford Marcella, Deputy
Assistant Secretary for Population
Affairs, Office of Population Affairs,
Office of the Assistant Secretary for
Health, Department of Health and
Human Services at Jessica.marcella@
hhs.gov and 240–453–2800.
SUPPLEMENTARY INFORMATION: Part A
(Office of the Secretary, U.S.
Department of Health and Human
Services) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (60 FR 56605, dated November
9, 1995, and corrected at 75 FR 53304,
August 31, 2010, amended at 82 FR
3005, dated January 10, 2017, and
amended, most recently at 84 FR 14951,
dated April 12, 2019) is amended to
reflect the reorganization of the Office of
Population Affairs (OPA), Office of the
Assistant Secretary for Health (OASH).
This reorganization will streamline
operations and improve the efficiency
and effectiveness of OPA. OPA is
responsible for implementing and
administering the Title X family
planning program, managing the Office
of Adolescent Health, which is headed
by a director, and implementing and
administering the Teen Pregnancy
Prevention program and other
adolescent health activities. The
changes are as follows:
I. Under Part C, section C–G,
Organization, revise to organize OPA
staff across six Divisions:
Administration and Operations,
Adolescent Health Programs, Clinical
and Scientific Affairs, Policy and
External Affairs, Research and
Evaluation, and Title X Service
Delivery. The Division of
Administration and Operations will
manage overall operations for OPA,
including staff recruitment and
retention, budgeting, training, and
travel. The Division of Adolescent
Health Programs will lead
implementation of the Teen Pregnancy
Prevention Program and other
adolescent health programmatic
activities. The Division of Clinical and
Scientific Affairs will provide clinical
and scientific expertise, consultation,
and oversight for all OPA staff and
activities. The Division of Policy and
External Affairs will lead all policy and
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:13 May 20, 2024
Jkt 262001
communication activities for the office.
The Division of Research and
Evaluation will oversee data collection
for OPA programs and will lead OPA’s
research and evaluation activities. The
Division of Title X Service Delivery will
lead implementation of the Title X
service delivery program.
II. Delegations of Authority: All
delegations and redelegations of
authority made to officials and
employees of affected organizational
components will continue in them or
their successors pending further
redelegations, if allowed, provided they
are consistent with this reorganization.
(Authority: 44 U.S.C. 3101)
Xavier Becerra,
Secretary, U.S. Department of Health and
Human Services.
[FR Doc. 2024–11058 Filed 5–20–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Neurological Sciences
Training Initial Review Group; NST–4 Study
Section.
Date: June 14, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Steven G Britt, MD,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH/HHS NSC, 6001 Executive
Boulevard, Rockville, MD 20852, 301–480–
1953, steve.britt@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Emphasis Panel; Review of UE5 Training
Applications.
Date: July 12, 2024.
Time: 2:30 p.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: William C. Benzing, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH/HHS NSC, 6001 Executive
Boulevard, Rockville, MD 20852, 301–496–
0660, benzingw@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS).
Dated: May 15, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–11067 Filed 5–20–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; HEAL
Initiative: Translating Research To Practice to
End the Overdose Crisis.
Date: June 27, 2024.
Time: 10:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Division of
Extramural Review, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC,
E:\FR\FM\21MYN1.SGM
21MYN1
]]>Agencies
[Federal Register Volume 89, Number 99 (Tuesday, May 21, 2024)]
[Notices]
[Page 44688]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11067]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Neurological Sciences Training Initial Review
Group; NST-4 Study Section.
Date: June 14, 2024.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Steven G Britt, MD, Scientific Review Officer,
Scientific Review Branch, Division of Extramural Activities, NINDS/
NIH/HHS NSC, 6001 Executive Boulevard, Rockville, MD 20852, 301-480-
1953, [email protected].
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Review of UE5 Training
Applications.
Date: July 12, 2024.
Time: 2:30 p.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: William C. Benzing, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH/HHS NSC, 6001 Executive Boulevard, Rockville,
MD 20852, 301-496-0660, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS).
Dated: May 15, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-11067 Filed 5-20-24; 8:45 am]
BILLING CODE 4140-01-P
